Nulan, YeldosYeldosNulanFelli, EricEricFelli0000-0002-5664-6746Selicean, Sonia-EmiliaSonia-EmiliaSeliceanPrampolini, ManuelManuelPrampoliniBerzigotti, AnnalisaAnnalisaBerzigotti0000-0003-4562-9016Gracia-Sancho, JordiJordiGracia-SanchoBosch, JaumeJaumeBosch2026-02-112026-02-112026-03https://boris-portal.unibe.ch/handle/20.500.12422/231638Background & Aims Cirrhosis increases hepatic vascular resistance (IHVR) by disrupting liver architecture due to fibrosis, and by elevating hepatic vascular tone due to hepatic endothelial dysfunction. IHVR increases portal pressure (PP), later aggravated by increased portal blood inflow. Carvedilol, a third-generation non-selective β-blocker with anti-α1-adrenergic activity, reduces PP more than propranolol, likely decreasing IHVR. However, its intrahepatic effects remain largely unexplored. This study aimed to address these issues. Methods Human cell lines (LX2 and HUVECs) and primary liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HSCs) isolated from cirrhotic rats (12-week thioacetamide [TAA] model) were treated with vehicle, carvedilol (10 μM), or propranolol (10 μM). Nitric oxide release, oxidative stress, and cell contraction were assessed. Cirrhotic rats were treated with vehicle, carvedilol (10 mg/kg/day for 2 weeks), or propranolol (30 mg/kg/day for 2 weeks) at early and advanced stages of cirrhosis (9 and 12 weeks of TAA). Hepatic hemodynamics, liver fibrosis, antioxidant activity, and inflammatory biomarkers were evaluated. Results Carvedilol increased nitric oxide release in LSECs and HUVECs and significantly reduced contraction of HSCs and LX2 cells in cirrhotic conditions. In vivo, carvedilol significantly reduced PP in both early and advanced cirrhosis (12-week TAA: -22%, p = 0.0008; 9-week TAA: -17%, p = 0.0038), decreased liver fibrosis area (-26.8%, p = 0.0013 vs. -23.1%, p = 0.0047), and reduced α-SMA expression (-22.7%, p = 0.0018 vs. -17.4%, p = 0.0455). Additionally, carvedilol improved endothelial dysfunction and reduced oxidative stress and inflammation. Propranolol did not exert these beneficial effects and produced a smaller, non-significant reduction in PP (-7%, p = 0.4029). Conclusions The greater reduction in PP achieved with carvedilol is mediated not only by its non-selective β-blocker effects but, more importantly, by its ability to reverse hepatic endothelial dysfunction, reduce fibrosis, enhance antioxidant activity, and exert moderate anti-inflammatory effects. These findings support extending the use of carvedilol even to patients without overt signs of portal hypertension. Impact And Implications Carvedilol is considered the best β-blocker for treating portal hypertension. In this study we show that carvedilol, unlike traditional β-blockers such as propranolol, downregulates the factors that lead to increased portal pressure in cirrhosis: it lowers the hepatic vascular tone by counteracting hepatic sinusoidal endothelial dysfunction, and decreases liver fibrosis by deactivating hepatic stellate cells and inhibiting their proliferation. On top of decreasing portal vein inflow via its non-selective β-blocker effect. Moreover, through its antioxidant and anti-inflammatory activity, it may contribute to improving liver function. These effects are noted both in early and in advanced cirrhosis, suggesting that it can be effective in slowing/reversing disease progression when associated with etiological therapy.enChronic liver diseaseNSBBsnon-selective beta blockersportal hypertension600 - Technology::610 - Medicine & healtharticle10.48620/945764165976910.1016/j.jhepr.2025.101681